SRPT Sarepta Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 873303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.9%
TTM net income YoY19.4%
TTM EPS YoY19.9%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2.5%
Net margin-5.9%
FCF margin9.0%
EBITDA margin-0.9%
Returns
ROE-7.6%
ROA-3.4%
ROIC (approx.)-2.5%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets51.7%
Debt / equity0.66x
Current ratio3.46x
Interest coverage0.62x
Cash quality & payout
Operating cash flow / net income-1.62x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $381.35M | $401.25M | $730.80M | $442.93M | $399.36M | $611.09M | $744.86M | $658.41M |
| Gross profit | — | — | — | -$29.10M | $219.27M | $360.56M | $473.96M | $505.85M |
| R&D expense | $82.55M | $91.26M | $153.96M | $325.34M | $218.89M | $204.39M | $773.45M | $199.95M |
| SG&A expense | $118.61M | $107.60M | $108.95M | $128.30M | $91.89M | $137.90M | $133.63M | $163.87M |
| Operating income | -$9.04M | $13.29M | $358.43M | -$411.58M | -$103.39M | $115.58M | -$300.39M | $161.68M |
| Interest expense | $21.62M | -$21.51M | -$21.71M | -$57.33M | $9.46M | -$5.23M | -$4.50M | -$32.31M |
| Pretax income | -$25.77M | -$1.75M | $343.17M | -$407.68M | -$64.67M | $153.64M | -$383.52M | $171.74M |
| Income tax | $2.69M | $3.14M | $12.21M | $4.55M | -$14.10M | -$43.25M | $63.99M | $12.69M |
| Net income | -$28.46M | -$4.89M | $330.96M | -$412.23M | -$50.57M | $196.89M | -$447.51M | $159.05M |
| EBITDA | -$3.14M | $23.70M | $369.03M | -$406.33M | -$84.94M | $126.42M | -$290.41M | $172.14M |
| EPS (basic) | -0.27 | -0.05 | 3.15 | -3.93 | -0.50 | 2.01 | -4.60 | 1.65 |
| EPS (diluted) | -0.27 | -0.05 | 2.88 | -3.93 | -0.50 | 1.89 | -4.60 | 1.50 |
| Weighted avg. shares (diluted) | 105.93M | 105.43M | 121.92M | — | 100.24M | 106.62M | 97.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $472.76M | $571.15M | $464.45M | $801.28M | $613.08M | $510.60M | $240.87M | $1.12B |
| Short-term investments | $406.02M | $217.34M | $188.74M | $138.37M | $237.92M | $289.54M | $281.89M | $251.78M |
| Receivables | $369.18M | $376.82M | $394.82M | $398.23M | $395.74M | $527.29M | $659.37M | $601.99M |
| Inventory | $876.12M | $904.27M | $1.00B | $914.74M | $1.08B | $994.04M | $941.43M | $749.96M |
| Current assets | $2.27B | $2.22B | $2.31B | $2.54B | $2.72B | $2.66B | $2.43B | $3.07B |
| PP&E, net | $319.29M | $325.99M | $336.24M | $345.12M | $358.94M | $371.86M | $360.59M | $340.34M |
| Intangibles | $29.83M | $30.61M | $31.38M | $28.95M | $29.68M | $30.52M | $26.20M | $26.89M |
| Total assets | $3.17B | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B |
| Current liabilities | $656.35M | $502.91M | $499.16M | $1.10B | $921.42M | $919.95M | $605.59M | $731.68M |
| Short-term debt | $157.97M | — | — | $0 | — | — | — | $0 |
| Long-term debt | $857.36M | $847.62M | $838.16M | $828.97M | $140.50M | — | — | $1.14B |
| Total debt | $1.02B | $847.62M | $838.16M | $828.97M | $140.50M | — | — | $1.14B |
| Total liabilities | $1.64B | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B |
| Shareholders' equity | $1.53B | $1.53B | $1.51B | $1.14B | $1.50B | $1.40B | $1.19B | $1.53B |
| Net debt | $542.58M | $276.48M | $373.71M | $27.69M | -$472.58M | — | — | $18.54M |
| Shares outstanding | 107.23M | 105.62M | 105.57M | 104.96M | 104.77M | 97.71M | 98.25M | 96.90M |
| Cash flow statement | ||||||||
| Operating cash flow | $59.97M | $197.07M | -$202.68M | $131.21M | -$14.59M | $261.34M | -$583.44M | $92.05M |
| Capital expenditure | $2.93M | $555,000 | $2.08M | $3.59M | $22.93M | $31.80M | $43.65M | $38.08M |
| Free cash flow | $57.03M | $196.51M | -$204.76M | $127.61M | -$37.52M | $229.54M | -$627.09M | $53.96M |
| Investing cash flow | -$158.35M | -$93.37M | -$134.39M | $96.21M | $232.40M | $32.21M | -$291.18M | $764.12M |
| Financing cash flow | $0 | $0 | $241,000 | -$39.21M | -$117.79M | -$23.82M | $12.47M | $48.99M |
| Depreciation & amortization | $5.90M | $10.41M | $10.59M | $5.25M | $18.45M | $10.84M | $9.98M | $10.46M |
| Stock-based compensation | $26.70M | $24.50M | $29.40M | $30.02M | $14.90M | $37.00M | $41.43M | $49.68M |
| Share buybacks | — | — | — | $0 | $0 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.